| scholarly article | Q13442814 |
| P50 | author | Eric J. Topol | Q5387640 |
| Deepak L. Bhatt | Q47264894 | ||
| P2860 | cites work | Identification of the platelet ADP receptor targeted by antithrombotic drugs | Q24290845 |
| Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain | Q24304907 | ||
| CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells | Q24310570 | ||
| Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides | Q24530304 | ||
| Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients | Q24555072 | ||
| Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin | Q24563384 | ||
| Arp2/3 complex is required for actin polymerization during platelet shape change | Q24603149 | ||
| Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study | Q28165115 | ||
| Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery | Q28175229 | ||
| Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials | Q28175861 | ||
| Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials | Q28176219 | ||
| Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial | Q28176922 | ||
| Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel | Q28181620 | ||
| Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial | Q28185728 | ||
| Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial | Q28185738 | ||
| The P2Y12 receptor as a therapeutic target in cardiovascular disease | Q28186432 | ||
| Profile and prevalence of aspirin resistance in patients with cardiovascular disease | Q28186905 | ||
| Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | Q28188284 | ||
| Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis | Q28189056 | ||
| Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein | Q28189164 | ||
| Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes | Q28191744 | ||
| Common variations in platelet glycoproteins: pharmacogenomic implications | Q28191774 | ||
| Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. | Q45238823 | ||
| Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. | Q50336029 | ||
| Increased levels of soluble P-selectin in hypercholesterolemic patients. | Q50898407 | ||
| Activated platelets in subjects at increased risk of IDDM. DENIS Study Group. Deutsche Nikotinamid Interventionsstudie. | Q51575576 | ||
| Anti-human von willebrand factor monoclonal antibody AJvW-2 prevents thrombus deposition and neointima formation after balloon injury in guinea pigs. | Q52164347 | ||
| RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. | Q54014329 | ||
| Abciximab reduces mortality in diabetics following percutaneous coronary intervention. | Q54057930 | ||
| Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. | Q54077482 | ||
| Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. | Q54101915 | ||
| Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model | Q56944726 | ||
| Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin | Q56944874 | ||
| Platelet GPIIb-IIIa blockers | Q56944972 | ||
| Prior aspirin use predicts worse outcomes in patients with non–ST-elevation acute coronary syndromes11This study was sponsored by COR Therapeutics Inc., South San Francisco, California; and Schering-Plough Research Institute, Kenilworth, New Jersey | Q56944980 | ||
| Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial | Q58771623 | ||
| Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy | Q59356566 | ||
| Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury | Q28191775 | ||
| Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting | Q28191931 | ||
| Aspirin for the primary prevention of cardiovascular events: recommendation and rationale | Q28192095 | ||
| Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force | Q28192096 | ||
| Underuse of aspirin in a referral population with documented coronary artery disease | Q28192543 | ||
| Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events | Q28192726 | ||
| Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus | Q28193753 | ||
| Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial | Q28194232 | ||
| ADAMTS13 and TTP | Q28217353 | ||
| Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity | Q28364491 | ||
| Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men | Q29619308 | ||
| Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration | Q29619529 | ||
| A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee | Q29620666 | ||
| Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis | Q30663963 | ||
| A model of platelet aggregation involving multiple interactions of thrombospondin-1, fibrinogen, and GPIIbIIIa receptor | Q31625659 | ||
| Oral glycoprotein IIb/IIIa antagonists in coronary artery disease | Q31805135 | ||
| Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. | Q31929744 | ||
| Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting | Q33328098 | ||
| Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. | Q33332419 | ||
| Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study | Q33333456 | ||
| Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization | Q33337811 | ||
| A new name in thrombosis, ADAMTS13. | Q33343892 | ||
| Platelets, acute inflammation and inflammatory mediators | Q33501223 | ||
| The STIMS trial: the ticlopidine experience and its clinical applications. Swedish Ticlopidine Multicenter Study | Q33502157 | ||
| A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. | Q33504515 | ||
| Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease | Q33843641 | ||
| Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study | Q33869577 | ||
| Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice | Q33903557 | ||
| Terbogrel, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibition | Q33920785 | ||
| Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. | Q34010668 | ||
| Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes | Q34042095 | ||
| Role of thrombin signalling in platelets in haemostasis and thrombosis | Q34090283 | ||
| Update on clinical trials of antiplatelet therapy for cerebrovascular diseases | Q34092484 | ||
| Antiplatelet agents in stroke prevention. combination therapy: present and future | Q34092489 | ||
| Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction | Q34103271 | ||
| A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V. | Q34106615 | ||
| Reversal of thrombin-induced deactivation of CD39/ATPDase in endothelial cells by HMG-CoA reductase inhibition: effects on Rho-GTPase and adenosine nucleotide metabolism. | Q34133687 | ||
| Need to test the arterial inflammation hypothesis | Q34136541 | ||
| Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice | Q34156437 | ||
| Production and characterization of saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion to collagen | Q34362559 | ||
| CD40 signaling and plaque instability | Q34460843 | ||
| The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke | Q34462070 | ||
| The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease | Q34491599 | ||
| Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice | Q34500809 | ||
| A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group | Q34540010 | ||
| Thrombin receptor antagonists; recent advances in PAR-1 antagonist development | Q34673415 | ||
| Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials | Q34712338 | ||
| Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice | Q35160907 | ||
| CD40 ligation induces tissue factor expression in human vascular smooth muscle cells | Q35793488 | ||
| Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system | Q36216095 | ||
| Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow | Q39586331 | ||
| Soluble CD40L and cardiovascular risk in women | Q40677583 | ||
| Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury | Q40703820 | ||
| Platelet-leukocyte-cross-talk in diabetes mellitus | Q41719238 | ||
| A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation | Q41824616 | ||
| Defective platelet activation in G alpha(q)-deficient mice. | Q42547684 | ||
| Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model | Q42675581 | ||
| Cardiovascular biology. Small cells, big issues | Q43528325 | ||
| Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial | Q43614601 | ||
| Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group | Q43622066 | ||
| Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study | Q43623998 | ||
| Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy | Q43645306 | ||
| Resistance to thromboembolism in PI3Kgamma-deficient mice. | Q43711871 | ||
| Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction | Q43724527 | ||
| Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes | Q43815690 | ||
| Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? | Q43888690 | ||
| Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model | Q43926474 | ||
| Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial | Q43952384 | ||
| Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood | Q43957652 | ||
| Clopidogrel inhibits platelet adhesion and platelet-dependent mitogenesis in vascular smooth muscle cells | Q43962562 | ||
| Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling | Q43977694 | ||
| Functional significance of adenosine 5'-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate | Q44009240 | ||
| Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension | Q44012407 | ||
| CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species | Q44108438 | ||
| Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation | Q44161523 | ||
| Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization | Q44346890 | ||
| BIOMEDICINE: Contact-How Platelets Touch von Willebrand Factor | Q60265892 | ||
| Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study | Q71005782 | ||
| Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors | Q71827452 | ||
| Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus | Q72786073 | ||
| Elective stenting of the extracranial carotid arteries | Q73012605 | ||
| PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis | Q73073912 | ||
| Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa) | Q73129860 | ||
| Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa | Q73129885 | ||
| Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes | Q73193128 | ||
| Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets | Q73384671 | ||
| Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation | Q73462995 | ||
| Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists | Q73514248 | ||
| Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa | Q73573613 | ||
| Inflammation and thrombosis: the clot thickens | Q73702701 | ||
| Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine après Pontage Fémoro-Poplité and the Association Universitaire de Recherche en Chirurgie | Q73929485 | ||
| Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation | Q73936839 | ||
| Reduction of monocyte-platelet interaction and monocyte activation in patients receiving antiplatelet therapy after coronary stent implantation | Q74108269 | ||
| Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease | Q74172108 | ||
| Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization | Q74179989 | ||
| Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy | Q74315441 | ||
| Platelet glycoprotein Ibalpha HPA-2 Met/VNTR B haplotype as a genetic predictor of myocardial infarction and sudden cardiac death | Q74403919 | ||
| Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation | Q74411852 | ||
| Cardiovascular biology. Platelets and proteases | Q74481919 | ||
| Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction | Q74611574 | ||
| Platelet-derived CD40L: the switch-hitting player of cardiovascular disease | Q74627856 | ||
| Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors | Q77305508 | ||
| Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study | Q77431162 | ||
| Frontiers in interventional cardiology | Q77465380 | ||
| Ligation of CD40 onvascular smooth muscle cells mediates loss of interstitial collagen via matrix metalloproteinase activity | Q77500913 | ||
| Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis | Q77575527 | ||
| Platelet microparticles promote platelet interaction with subendothelial matrix in a glycoprotein IIb/IIIa-dependent mechanism | Q77756614 | ||
| Leptin promotes aggregation of human platelets via the long form of its receptor | Q77766009 | ||
| Effect of leptin on arterial thrombosis following vascular injury in mice | Q77855897 | ||
| Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes | Q78108701 | ||
| Attacked from within, blood thins | Q78306580 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 15-28 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | Scientific and therapeutic advances in antiplatelet therapy | |
| P478 | volume | 2 |
| Q37989558 | A contemporary viewpoint on 'aspirin resistance'. |
| Q33379144 | A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex |
| Q40329955 | A point-of-care assay to measure platelet aggregation in patients taking clopidogrel |
| Q62515572 | A shear gradient–dependent platelet aggregation mechanism drives thrombus formation |
| Q47286564 | ATP Evokes Ca2+ Responses and CXCL5 Secretion via P2X4 Receptor Activation in Human Monocyte-Derived Macrophages |
| Q37631402 | Antiplatelet Activity of Morus alba Leaves Extract, Mediated via Inhibiting Granule Secretion and Blocking the Phosphorylation of Extracellular-Signal-Regulated Kinase and Akt. |
| Q36215337 | Antiplatelet and antithrombotic effects of cordycepin-enriched WIB-801CE from Cordyceps militaris ex vivo, in vivo, and in vitro |
| Q43236396 | Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us? |
| Q35550212 | Antiplatelet therapy: in search of the 'magic bullet'. |
| Q38367551 | Antiplatelet, Antithrombotic, and Fibrinolytic Activities of Campomanesia xanthocarpa |
| Q78771103 | Antithrombotic drug market |
| Q37157980 | Antithrombotic effects of targeting alphaIIbbeta3 signaling in platelets |
| Q54950854 | Aortic Aneurysms. |
| Q28194021 | Aspirin and clopidogrel resistance: an emerging clinical entity |
| Q34771381 | Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance |
| Q28167475 | Aspirin resistance |
| Q28200100 | Aspirin resistance - does it clinically matter? |
| Q28217948 | Aspirin therapy for inhibition of platelet reactivity in the presence of erythrocytes in patients with vascular disease |
| Q41675317 | Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke |
| Q35854514 | Association between polymorphisms of platelet membrane glycoprotein Ibα and risk of coronary heart disease in Han Chinese, Henan, China |
| Q36067955 | BMI Affects the Relationship between Long Chain N-3 Polyunsaturated Fatty Acid Intake and Stroke Risk: a Meta-Analysis |
| Q37017170 | CD40/CD40L system and vascular disease. |
| Q41954849 | Calmodulin interacts with the platelet ADP receptor P2Y1 |
| Q28196152 | Can clopidogrel and aspirin lower mortality in patients with acute myocardial infarction? |
| Q26745591 | Capsaicin: Current Understanding of Its Mechanisms and Therapy of Pain and Other Pre-Clinical and Clinical Uses |
| Q35808289 | Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention |
| Q28218124 | Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease |
| Q64988468 | Clopidogrel Pharmacokinetics in Malaysian Population Groups: The Impact of Inter-Ethnic Variability. |
| Q28217704 | Clopidogrel-induced spontaneous spinal epidural hematoma |
| Q28168869 | Clopidogrel: how good is it and how does it work? |
| Q37989188 | Coagulopathy and hemostatic monitoring in cardiac surgery: an update |
| Q37765146 | Contemporary treatment of unstable angina and non-ST-segment-elevation myocardial infarction (part 2). |
| Q53471405 | Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay. |
| Q35154045 | Discovery of prognostic biomarker candidates of lacunar infarction by quantitative proteomics of microvesicles enriched plasma. |
| Q34064897 | Dissolution of pre-existing platelet thrombus by synergistic administration of low concentrations of bifunctional antibodies against β3 integrin |
| Q51819151 | Distinct roles of ligand affinity and cytoskeletal anchorage in alphaIIbbeta3 (GP IIb/IIIa)-mediated cell aggregation and adhesion. |
| Q30572399 | Dok-2 adaptor protein regulates the shear-dependent adhesive function of platelet integrin αIIbβ3 in mice |
| Q44523511 | Effect of hyperosmolarity on agonist-induced increases of intracellular calcium in human platelets |
| Q37155890 | Efficacy of clopidrogel on reperfusion and high-sensitivity C-reactive protein in patients with acute myocardial infarction |
| Q46830257 | Eptifibatide does not suppress the increase of inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome |
| Q53639170 | Facile fabrication of robust superhydrophobic multilayered film based on bioinspired poly(dopamine)-modified carbon nanotubes. |
| Q37841562 | Functional testing methods for the antiplatelet effects of aspirin |
| Q36753593 | Future innovations in anti-platelet therapies. |
| Q28513888 | G13 is an essential mediator of platelet activation in hemostasis and thrombosis |
| Q54466253 | GDF-15 prevents platelet integrin activation and thrombus formation. |
| Q38664158 | Global Trends in Aspirin Resistance-Related Research from 1990 to 2015: A Bibliometric Analysis |
| Q34997206 | Global analysis of the rat and human platelet proteome - the molecular blueprint for illustrating multi-functional platelets and cross-species function evolution. |
| Q28590644 | Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice. |
| Q36383364 | Identifying aberrant pathways through integrated analysis of knowledge in pharmacogenomics |
| Q41884542 | Impaired alpha(IIb)beta(3) integrin activation and shear-dependent thrombus formation in mice lacking phospholipase D1. |
| Q34065288 | Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects |
| Q35692019 | Inflammation and atherosclerosis |
| Q46683898 | Is prasugrel superior to clopidogrel for patients with acute coronary syndromes undergoing PCI? |
| Q45947043 | Label-free detection of aggregated platelets in blood by machine-learning-aided optofluidic time-stretch microscopy. |
| Q51806809 | Leucine-rich repeats 2-4 (Leu60-Glu128) of platelet glycoprotein Ibalpha regulate shear-dependent cell adhesion to von Willebrand factor. |
| Q33225547 | MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice |
| Q36741271 | Mechanisms and consequences of agonist-induced talin recruitment to platelet integrin alphaIIbbeta3 |
| Q38214959 | Mechanistic explanation for platelet contribution to cancer metastasis |
| Q40328019 | Megakaryocytes derived from human embryonic stem cells: a genetically tractable system to study megakaryocytopoiesis and integrin function. |
| Q34600570 | Molecular and functional differences induced in thrombospondin-1 by the single nucleotide polymorphism associated with the risk of premature, familial myocardial infarction |
| Q34837954 | NP-313, 2-acetylamino-3-chloro-1,4-naphthoquinone, a novel antithrombotic agent with dual inhibition of thromboxane A(2) synthesis and calcium entry. |
| Q38419319 | New horizons in platelet research: understanding and harnessing platelet functional diversity. |
| Q26865345 | Next-generation antithrombotics in ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis' |
| Q37887771 | Nitric oxide: a guardian for vascular grafts? |
| Q38073160 | Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor |
| Q52721231 | On the Role of Store-Operated Calcium Entry in Acute and Chronic Neurodegenerative Diseases. |
| Q35002507 | Onion (Allium cepa L.) peel extract has anti-platelet effects in rat platelets |
| Q43229563 | Optimization of ferric chloride induced thrombosis model in rats: effect of anti-platelet and anti-coagulant drugs. |
| Q37762149 | Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence |
| Q35636842 | P2Y12 or P2Y1 inhibitors reduce platelet deposition in a microfluidic model of thrombosis while apyrase lacks efficacy under flow conditions |
| Q33421448 | Perioperative use of iloprost in cardiac surgery patients diagnosed with heparin-induced thrombocytopenia-reactive antibodies or with true HIT (HIT-reactive antibodies plus thrombocytopenia): An 11-year experience |
| Q30492793 | Phosphoinositide 3-kinase p110 beta regulates integrin alpha IIb beta 3 avidity and the cellular transmission of contractile forces. |
| Q36004648 | Platelet Inhibitors Reduce Rupture in a Mouse Model of Established Abdominal Aortic Aneurysm |
| Q33442212 | Platelet distribution width as the prognostic marker in coronary bifurcation treatment |
| Q47637050 | Platelet factor XIII and calpain negatively regulate integrin alphaIIbbeta3 adhesive function and thrombus growth |
| Q33308465 | Platelet fragmentation requires a specific structural conformation of human monoclonal antibody against beta3 integrin |
| Q26749231 | Platelet function and ageing |
| Q28219354 | Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both? |
| Q36877378 | Platelet integrins and immunoreceptors |
| Q42177034 | Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site |
| Q37682009 | Platelet microparticles: a biomarker for recanalization in rtPA-treated ischemic stroke patients. |
| Q37071700 | Platelet receptor redox regulation |
| Q37032473 | Platelet retraction force measurements using flexible post force sensors |
| Q37081746 | Platelets as cellular effectors of inflammation in vascular diseases |
| Q26739670 | Platelets in Pulmonary Immune Responses and Inflammatory Lung Diseases |
| Q35765113 | Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications |
| Q37982427 | Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients |
| Q45988813 | Prasugrel. |
| Q38360688 | Privileged frameworks from snake venom. |
| Q43225359 | RGD-ligand mimetic antagonists of integrin alphaIIbbeta3 paradoxically enhance GPVI-induced human platelet activation. |
| Q33432275 | Rapid characterization of hybridomas producing monoclonal antibodies against platelet β3 integrin using ELIspot |
| Q28218351 | Recent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problems |
| Q37809630 | Review: Antiplatelet drugs: what comes next? |
| Q37618371 | Schisandra chinensis and Morus alba Synergistically Inhibit In Vivo Thrombus Formation and Platelet Aggregation by Impairing the Glycoprotein VI Pathway. |
| Q36996283 | Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function. |
| Q34023143 | Strategies for discovering and derisking covalent, irreversible enzyme inhibitors |
| Q36255844 | Studies on New Activities of Enantiomers of 2-(2-Hydroxypropanamido) Benzoic Acid: Antiplatelet Aggregation and Antithrombosis |
| Q24675155 | The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts |
| Q35868825 | The antithrombotic potential of selective blockade of talin-dependent integrin alpha IIb beta 3 (platelet GPIIb-IIIa) activation |
| Q37135540 | The calcium activated nucleotidases: A diverse family of soluble and membrane associated nucleotide hydrolyzing enzymes |
| Q30482557 | The calcium sensor STIM1 is an essential mediator of arterial thrombosis and ischemic brain infarction |
| Q34158362 | The constituents of roots and stems of Illigera luzonensis and their anti-platelet aggregation effects |
| Q35863108 | The inhibitory mechanism of crude saponin fraction from Korean Red Ginseng in collagen-induced platelet aggregation |
| Q38156780 | The platelet fibrinogen receptor: from megakaryocyte to the mortuary |
| Q38034249 | The potential of flavanol and procyanidin intake to influence age-related vascular disease |
| Q37903711 | The potential role of milk-derived peptides in cardiovascular disease |
| Q38191251 | The role of platelets in coagulation dysfunction in xenotransplantation, and therapeutic options. |
| Q28187576 | Therapeutic approaches in arterial thrombosis |
| Q50579051 | Utility of in vitro and in vivo systems for studying the permeability of capsaicin and nonivamide through different intestinal regions. |
| Q34954267 | Vipegitide: a folded peptidomimetic partial antagonist of α2β1 integrin with antiplatelet aggregation activity |
| Q84912890 | [Acute ischemic stroke. New approaches to antithrombotic treatment] |
| Q47613791 | alphaIIbbeta3 antagonism vs. antiadhesive treatment to prevent platelet interactions with vascular subendothelium |
| Q35642870 | mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets. |
Search more.